13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03282760 (ClinicalTrials.gov) | September 9, 2017 | 9/8/2017 | Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients | A Phase I Multicenter Study of Allogenic, Intracerebroventricular Human Neural Stem Cells Transplantation for the Experimental Treatment of Secondary Progressive Multiple Sclerosis Patients | Secondary-progressive Multiple Sclerosis | Biological: Human Neural Stem Cells | Casa Sollievo della Sofferenza IRCCS | Associazione Revert ONLUS;Neurocenter of Southern Switzerland;Fondazione Cellule Staminali | Active, not recruiting | 18 Years | 60 Years | All | 24 | Phase 1 | Italy;Switzerland |